LAB
Market cap | $795.33 Million |
---|---|
Enterprise Value | $388.00 Million |
Dividend Yield | $0.0 (0.0%) |
Earnings per Share | $-1.02 |
Beta | 0.0 |
Outstanding Shares | 369,920,511 |
Avg 30 Day Volume | 2,056,472 |
Return on Equity | - |
---|---|
Return on Assets | - |
Return on Invested Capital | - |
P/E Ratio | -5.85 |
---|---|
PEG | -1.61 |
Price to Sales | - |
Price to Book Ratio | 2.15 |
Enterprise Value to Revenue | 3.06 |
Enterprise Value to EBIT | -4.56 |
Enterprise Value to Net Income | -3 |
Total Debt to Enterprise | 0.14 |
Debt to Equity | 0.1 |
No data
No data
Fluidigm focuses on the most pressing needs in translational and clinical research, including cancer, immunology, and immunotherapy. Using proprietary CyTOF® and microfluidics technologies, it develops, manufactures, and markets multi-om...